drugset / Trial / NCT05278104

A Study to Test Different Ways to Measure the Effect of Atomoxetine on Impulsive Behavior in Young Adults With Attention Deficit Hyperactivity Disorder (ADHD)

NCT05278104

Completed 63 enrolled Boehringer Ingelheim
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objectives are to investigate the effect of atomoxetine on impulsivity after single dose and at steady state measured by the total score of Barrett Impulsiveness Scale version 11 (BIS-11) and Short Urgency, Perseverance, Premeditation, and Sensation Seeking-Positive Urgency Impulsive Behavior Scale (S-UPPS-P) Impulsive Behavior Scale. The secondary objective is to evaluate the safety of atomoxetine.

Timeline

Start
2023-09-14
Primary completion
2024-10-23
Completion
2024-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Atomoxetine Other / unclassified 80 mg Oral